With one click, developers can implement a Jira issue, whether a story, bug, task, or subtask, and the implementation will generate code from requirements in that issue, Tabnine said. Afterward, ...

He built interfaces that allowed engineers, scientists and everyday people to solve difficult problems without having to write the underlying code.

As tools like Claude Code get better, more and more developers are happy to hand off coding tasks to them. The way software gets built has changed for good. The vibes were strong at Code with Claude, ...

Linear error-correcting codes form the mathematical backbone of modern digital communication and storage systems, but identifying champion linear codes (linear codes achieving or exceeding the best ...

With Claude enjoying a moment of newfound popularity among regular people, Anthropic is previewing an update designed to make its chatbot better at explaining some concepts. Starting today, Claude can ...

AI coding agents have become one of the fastest-growing categories in enterprise software. In the span of just a few years, these development tools have evolved from simple autocomplete assistants ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines has earmarked $300 million of its IPO funds to complete a pair of phase 3 asthma trials for its anti-TSLP antibody GB-0895. (Fabrice Cabaud/Stock/Getty Images Plus) ...

Generate Biomedicines Inc. raised $400 million in an initial public offering, pricing its shares at the midpoint of the marketed range. The Somerville, Massachusetts-based drug developer sold 25 ...

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...

Generate Biomedicines, Inc. (GENB) has filed to raise public capital in an IPO to advance its pipeline of treatment candidates, according to an SEC filing. The company is developing treatments for ...